pocketful logo light
pocketful logo light
Lasa Supergenerics Ltd logo

Lasa Supergenerics Ltd

NSE: LASA BSE: 540702

7.51

(3.84%)

Thu, 25 Jun 2026, 05:10 am

Lasa Supergenerics Share Price Live Chart

1 Day

(3.84%)

No Result Found

Summary

  • Market Cap (in Cr)

    41.58

  • Net Profit (in Cr)

    -14.76

  • P/B

    1.03

  • Sector P/E

    44.89

  • P/E

    0

  • EV/EBITDA

    0

  • Debt/Equity (Industry)

    0.24

  • Interest Cover (Industry)

    9.79

  • ROCE (Industry)

    14.04

  • RONW (Industry)

    13.17

  • ROE

    0

  • ROCE

    0

  • Debt/Equity

    0.13

  • EPS (TTM)

    0.05

  • Dividend Yield

    0

  • Book Value

    11.25

  • Interest Cover

    -0.38

Analysis

No Result Found

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters53.6553.6553.6553.6553.65
FII00000
DII00000
Public46.3546.3546.3546.3546.35
Government00000

Read More

Technical Analysis

RSI

48.33

MACD

-0.10

50 DMA

7.93

200 DMA

9.18

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic10.659.438.878.217.656.995.77
Fibonacci9.438.968.688.217.747.466.99
Camarilla8.658.538.428.218.208.097.97

Pivots Level: Classic

R3

+2.44

10.65

R2

+1.22

9.43

R1

+0.66

8.87

8.21
8.21
Pivot Point
LTP: 7.59

S1

-0.56

7.65

S2

-1.22

6.99

S3

-2.44

5.77

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    7.54

  • 20-EMA

    7.61

  • 30-EMA

    7.67

  • 50-EMA

    7.77

  • 100-EMA

    8.15

  • 200-EMA

    9.63

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
29 May 2026board-meetingsAccounts, Quarterly Results
13 Feb 2026board-meetingsQuarterly Results
14 Nov 2025board-meetingsQuarterly Results
05 Sept 2025agm
28 Jan 2025egm
03 Sept 2024agm
20 Aug 2024agmAnnual General Meeting21 Sept 2024
02 Sept 2023agm
20 Aug 2023agmAnnual General Meeting21 Sept 2023
05 Sept 2022agm

Read More

Peer Comparison

Lasa Supergenerics Ltd logo

Lasa Supergenerics Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Read More

Lasa Supergenerics Ltd About

Lasa Supergenerics is primarily engaged in the business of manufacturing API bulk drugs products.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

2016

Headquarters

CEO

Omkar P Herlekar

Employees

Contact

Website icon

Website

http://www.lasalabs.com

Email icon

Email

cs@lasalabs.com

Phone icon

Phone

91-2145-232101/232202

Location icon

Location

C-105 MIDC, Mahad, Raigad, Maharashtra, 402301

Read More

Lasa Supergenerics Ltd Company History

YearHistory
2013
  • The Companies Act was established.
2016
  • Lasa Supergenerics Limited was incorporated as a public limited company.
2021
  • LASA launched new product Oxyclozanide Creating new Capacity as a brown field expansion.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
AMIT KUMAR JAIN HUFbulkBuy39811310.5708 Sept 2025
AMIT KUMAR JAIN HUFbulkSell22460610.6508 Sept 2025
BNP ENTERPRISESbulkSell28454217.2822 May 2025
MANBHUPINDER SINGH ATWALbulkSell28000028.3801 Jan 2024
MANBHUPINDER SINGH ATWALbulkBuy30000032.827 Dec 2023
PALAK INTERMEDIATES PRIVATE LIMITEDbulkBuy27083830.5917 Feb 2023
PALAK INTERMEDIATES PRIVATE LIMITEDbulkSell27083829.9617 Feb 2023
PALAK INTERMEDIATES PRIVATE LIMITEDbulkBuy77340729.0616 Feb 2023
PALAK INTERMEDIATES PRIVATE LIMITEDbulkSell77340729.1316 Feb 2023
SKSE SECURITIES LTDbulkBuy32789141.3921 Sept 2022

Read More

Lasa Supergenerics Ltd News

Lasa Supergenerics promoter discloses FY26 status

Omkar Herlekar reported no new share encumbrances in FY26. The disclosure was made under SEBI (SAST) Regulations.

02 Jun 2026

companies

LASA Supergenerics Q4FY26 related party transactions

LASA Supergenerics disclosed related party transactions for Q4FY26, including remuneration and donations totaling ₹35.36 lakh.

30 May 2026

companies

Lasa Supergenerics reports Q4FY26 net loss

Lasa Supergenerics reported a net loss of ₹416.44 lakh for Q4FY26. Revenue from operations stood at (₹13.15) lakh.

29 May 2026

companies

Lasa Supergenerics Board Meet Set for May 29, 2026

Lasa Supergenerics schedules board meeting on May 29, 2026 to approve audited financial results for Q4 and full year ended March 31, 2026.

19 May 2026

companies

LASA Supergenerics Declares Non-Applicability of Large Entity Framework

LASA Supergenerics Limited has declared that it falls outside the purview of the Large Corporate category as per SEBI's framework for debt securities issuance by large entities.

16 Apr 2026

companies

Read More

Open Your Free Demat Account

Enter your phone number